Zai Lab/$ZLAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Zai Lab
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
Ticker
$ZLAB
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
1,869
ISIN
US98887Q1040
Website
Zai Lab Metrics
BasicAdvanced
$4.1B
-
-$2.48
0.95
-
Price and volume
Market cap
$4.1B
Beta
0.95
52-week high
$44.34
52-week low
$16.01
Average daily volume
1M
Financial strength
Current ratio
3.258
Quick ratio
2.642
Long term debt to equity
1.519
Total debt to equity
23.718
Interest coverage (TTM)
-80.56%
Profitability
EBITDA (TTM)
-255.817
Gross margin (TTM)
5.94%
Net profit margin (TTM)
-60.26%
Operating margin (TTM)
-64.09%
Revenue per employee (TTM)
$220,000
Management effectiveness
Return on assets (TTM)
-15.50%
Return on equity (TTM)
-32.05%
Valuation
Price to revenue (TTM)
8.973
Price to book
4.94
Price to tangible book (TTM)
5.33
Price to free cash flow (TTM)
-15.716
Free cash flow yield (TTM)
-6.36%
Free cash flow per share (TTM)
-234.99%
Growth
Revenue change (TTM)
43.72%
Earnings per share change (TTM)
-29.08%
3-year revenue growth (CAGR)
34.76%
3-year earnings per share growth (CAGR)
-24.85%
What the Analysts think about Zai Lab
Analyst ratings (Buy, Hold, Sell) for Zai Lab stock.
Bulls say / Bears say
Zai Lab's net product revenue increased by 21% year-over-year in Q1 2025, indicating strong sales growth. (BioSpace)
The company announced positive topline results from the Phase 3 PANOVA-3 clinical trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer, potentially expanding its oncology portfolio. (Zai Lab Press Release)
Zai Lab's inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC in China's National Reimbursement Drug List could significantly boost sales in the Chinese market. (Zai Lab Press Release)
Despite revenue growth, Zai Lab reported a net loss of $48.4 million in Q1 2025, reflecting ongoing profitability challenges. (BioSpace)
The company's debt-to-equity ratio has increased to 10% over the past five years, indicating a rising debt burden. (Simply Wall St)
Zai Lab's operating expenses, including R&D and SG&A, remain high, which may pressure margins and delay profitability. (BioSpace)
Data summarised monthly by Lightyear AI. Last updated on 11 Jun 2025.
Zai Lab Financial Performance
Revenues and expenses
Zai Lab Earnings Performance
Company profitability
Zai Lab News
AllArticlesVideos
Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025
Business Wire·1 week ago
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
Business Wire·3 weeks ago
Zai Lab Announces Participation in Investor Conferences in June 2025
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Zai Lab stock?
Zai Lab (ZLAB) has a market cap of $4.1B as of June 20, 2025.
What is the P/E ratio for Zai Lab stock?
The price to earnings (P/E) ratio for Zai Lab (ZLAB) stock is 0 as of June 20, 2025.
Does Zai Lab stock pay dividends?
No, Zai Lab (ZLAB) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Zai Lab dividend payment date?
Zai Lab (ZLAB) stock does not pay dividends to its shareholders.
What is the beta indicator for Zai Lab?
Zai Lab (ZLAB) has a beta rating of 0.95. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.